Tags

Type your tag names separated by a space and hit enter

The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.
Clin Neuropharmacol. 2006 May-Jun; 29(3):106-11.CN

Abstract

Levodopa treatment of Parkinson disease results in hyperhomocysteinemia (HHcy) as a consequence of levodopa methylation by catechol-O-methyltransferase (COMT). Although inhibition of COMT should theoretically prevent or reduce levodopa-induced HHcy, results from several prospective studies are conflicting. Our review of these studies suggests that the ability of COMT inhibition to reduce or prevent levodopa-induced HHcy in Parkinson disease patients may be attributed to differences in the vitamin status of the study participants. In patients with low or low-normal folate levels, levodopa administration is associated with a greater increase in homocysteine and concomitant entacapone administration is associated with a greater reduction in homocysteine.

Authors+Show Affiliations

Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, 33612, USA. tzesiewi@hsc.usf.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

16772808

Citation

Zesiewicz, Theresa A., et al. "The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated With Levodopa Alone or With Entacapone: Effects of Vitamin Status." Clinical Neuropharmacology, vol. 29, no. 3, 2006, pp. 106-11.
Zesiewicz TA, Wecker L, Sullivan KL, et al. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol. 2006;29(3):106-11.
Zesiewicz, T. A., Wecker, L., Sullivan, K. L., Merlin, L. R., & Hauser, R. A. (2006). The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clinical Neuropharmacology, 29(3), 106-11.
Zesiewicz TA, et al. The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated With Levodopa Alone or With Entacapone: Effects of Vitamin Status. Clin Neuropharmacol. 2006 May-Jun;29(3):106-11. PubMed PMID: 16772808.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. AU - Zesiewicz,Theresa A, AU - Wecker,Lynn, AU - Sullivan,Kelly L, AU - Merlin,Lisa R, AU - Hauser,Robert A, PY - 2006/6/15/pubmed PY - 2006/7/28/medline PY - 2006/6/15/entrez SP - 106 EP - 11 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 29 IS - 3 N2 - Levodopa treatment of Parkinson disease results in hyperhomocysteinemia (HHcy) as a consequence of levodopa methylation by catechol-O-methyltransferase (COMT). Although inhibition of COMT should theoretically prevent or reduce levodopa-induced HHcy, results from several prospective studies are conflicting. Our review of these studies suggests that the ability of COMT inhibition to reduce or prevent levodopa-induced HHcy in Parkinson disease patients may be attributed to differences in the vitamin status of the study participants. In patients with low or low-normal folate levels, levodopa administration is associated with a greater increase in homocysteine and concomitant entacapone administration is associated with a greater reduction in homocysteine. SN - 0362-5664 UR - https://www.unboundmedicine.com/medline/citation/16772808/The_controversy_concerning_plasma_homocysteine_in_Parkinson_disease_patients_treated_with_levodopa_alone_or_with_entacapone:_effects_of_vitamin_status_ L2 - https://doi.org/10.1097/01.WNF.0000220817.94102.95 DB - PRIME DP - Unbound Medicine ER -